Indie Games [2026]: 9 Hidden Gems Worth Your Time and Money

Cardio has gone through several narrative cycles in fitness culture — from essential, to optional if you strength train, to Zone 2 being the answer to everything. The actual evidence is more specific and more nuanced than any of these cycles suggests. Here is what the research shows you actually need and why.

What the Current Guidelines Actually Say

The World Health Organization, American Heart Association, and most major health bodies currently recommend 150-300 minutes per week of moderate-intensity aerobic activity, or 75-150 minutes of vigorous-intensity activity, for meaningful cardiovascular health benefit. The "moderate intensity" threshold is roughly the level at which you can hold a conversation but feel noticeably elevated effort — brisk walking, easy cycling, light jogging. This is a threshold that most sedentary adults don't meet, and the research shows significant health benefit from any increase toward this target, even from very low baselines.

The most important finding from cardiovascular research: the relationship between cardio and health outcomes shows the largest benefits at the transition from sedentary to some exercise. The difference between zero cardio and 90-150 minutes per week is enormous in terms of health outcomes. The difference between 150 minutes and 300 minutes per week is real but much smaller. If you're currently doing nothing, doing something modest produces dramatic relative benefit. The pressure to optimize beyond the basic recommendation is, for most people's purposes, a form of fitness culture perfectionism that distracts from the more important step of simply moving more.

Zone 2 Training: What It Is and Who It's For

Zone 2 training — low-intensity aerobic exercise sustained for long durations (45-90+ minutes per session), at an intensity where you can maintain a full conversation without shortness of breath — has received significant attention in longevity and performance circles. The claimed benefits: mitochondrial density improvements, fat oxidation capacity, and aerobic base building that supports higher-intensity training. These benefits are real and supported by research, primarily in endurance athlete contexts.

The honest context: Zone 2 training is genuinely valuable for endurance athletes and people optimizing for longevity metrics. It's not a replacement for moderate-to-vigorous cardio for most health purposes, and the time commitment (45-90 minutes per session, multiple sessions per week) is unrealistic for most people's schedules. For non-athletes, the practical recommendation is simply to do cardio you'll actually sustain — brisk walking, cycling, running, swimming, whatever you'll do consistently — rather than optimizing intensity distribution before you have a consistent base.

Running: The Most Accessible Cardio

Running is the cardio modality with the most consistent data and the lowest equipment barrier. The injury rate for new runners is real (shin splints, knee pain, and plantar fasciitis are common early experiences) and is primarily attributable to increasing volume too quickly. The 10% rule — don't increase weekly mileage by more than 10% per week — is a reasonable heuristic for injury prevention. Starting with run-walk intervals (Couch to 5K is the most accessible structured beginner program) rather than trying to run continuously from the first session produces better outcomes for most new runners.

The long-term benefits of regular running — cardiovascular health, cognitive function, longevity — are among the best-documented in exercise research. The "running ruins your knees" concern is largely unsupported by the research, which actually shows lower rates of knee arthritis in recreational runners compared to non-runners in some studies.

My honest take: 150 minutes per week of anything that elevates your heart rate meaningfully. Do cardio you'll actually sustain. Zone 2 is valuable optimization for people who already exercise consistently — not the starting point. For beginners, Couch to 5K.